PT-141 (Bremelanotide) Research Guide — Central Melanocortin Signalling

Research Use Only. All OL Research products are supplied strictly for in-vitro and laboratory research purposes. They are not medicines, food supplements, or cosmetic ingredients. Not for human or veterinary use. This article is written for educational and scientific reference only.

What is PT-141 (Bremelanotide)?

PT-141, also known by the INN bremelanotide, is a synthetic cyclic heptapeptide melanocortin receptor agonist. Structurally, it is the des-amidated (C-terminal hydroxyl rather than amide) form of Melanotan II, with the sequence Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH. Despite this apparently minor modification, the pharmacological profile of PT-141 differs meaningfully from Melanotan II — most notably in its reduced affinity for MC1R (the receptor mediating skin pigmentation) relative to its potent MC3R and MC4R agonism.

PT-141 was originally identified as a metabolite of Melanotan II during pharmacokinetic research and subsequently developed as a more receptor-selective research compound. Its molecular weight is approximately 1025.2 Da.

Melanocortin Receptor Selectivity: PT-141 vs Melanotan II

The critical pharmacological distinction between PT-141 and its parent Melanotan II lies in receptor selectivity. Melanotan II binds with high affinity to MC1R, MC3R, MC4R, and MC5R. PT-141 retains potent MC3R and MC4R agonism but has substantially reduced MC1R affinity, making it less effective at stimulating melanogenesis. This selectivity shift was pharmacologically significant because it allowed research to focus on the central melanocortin axes (MC3R and MC4R in the CNS) with less confounding from peripheral pigmentation effects.

Researchers studying either compound in detail should consult our PT-141 vs Melanotan II comparison guide for a detailed receptor binding and structure-activity comparison, and our Melanotan II research guide for coverage of the MC1R-mediated pigmentation axis.

Central Melanocortin Signalling: MC3R and MC4R

MC4R is densely expressed in the hypothalamic paraventricular nucleus, arcuate nucleus, dorsomedial nucleus, and the nucleus accumbens, as well as in limbic regions including the medial amygdala. MC3R is expressed in the hypothalamus, hippocampus, and brainstem. Together, these receptors integrate signals from the leptin-melanocortin pathway to regulate energy balance, reproductive behaviour, and reward circuitry.

The significance of the MC4R for central biology was established through genetic studies: MC4R knockout mice display hyperphagia, obesity, and hyperinsulinaemia, while heterozygous MC4R loss-of-function mutations are the most common single-gene cause of severe human obesity. Beyond energy regulation, MC4R signalling in limbic areas has been linked to arousal, mood, and motivational states — a set of functions that has made the receptor an intensive target for pharmacological investigation.

CNS Mechanism Distinguished from PDE5 Inhibitors

One mechanistically important distinction in PT-141 research is the central, CNS-mediated nature of MC4R signalling, in contrast to the peripheral vasodilatory mechanism of PDE5 inhibitors (such as sildenafil). PDE5 inhibitors act on vascular smooth muscle in penile and clitoral erectile tissue by preventing cGMP degradation, promoting vasodilation. PT-141’s MC4R mechanism, by contrast, operates centrally — activating hypothalamic and limbic circuits involved in arousal and motivational states.

This mechanistic distinction has important implications for research design. Studies investigating PT-141’s central mechanism typically use stereotaxic CNS injection in rodent models, quantify downstream neuropeptide and neurotransmitter changes (dopamine, oxytocin), and use c-Fos immunohistochemistry to map activated neural circuits following MC4R stimulation. Peripheral versus central administration paradigms are used to distinguish central from peripheral contributions to observed effects.

Receptor Binding Assays and Research Methodology

PT-141’s receptor pharmacology has been characterised extensively using competitive binding assays with radiolabelled α-MSH analogues, cAMP accumulation assays (MC1-5R are Gs-coupled, stimulating adenylyl cyclase), and functional cell-based assays using CHO or HEK293 cells stably expressing individual MCRs. Ki values and EC50 values derived from these assays allow quantitative comparison of PT-141, MT-II, and other MCR ligands, including the endogenous antagonists ASIP and AgRP.

In behavioural research, standardised rodent models are used to assess the functional consequences of central MC3R/MC4R activation following PT-141 administration. These protocols require institutional ethical approval and adherence to established animal research guidelines.

Relationship to the KPV and Alpha-MSH Anti-Inflammatory Axis

While PT-141 research is primarily oriented towards central MC3R/MC4R biology, it is worth noting the broader anti-inflammatory properties of the melanocortin system. MC1R and MC3R activation — by α-MSH and its fragments — is associated with suppression of NF-κB and reduction of pro-inflammatory cytokine production. Our KPV peptide research guide covers the tripeptide C-terminal fragment of α-MSH and its anti-inflammatory research applications in intestinal biology.